文献速递慢性肾脏病肾血管病与高血压

代谢功能障碍相关脂肪性肝病与慢性肾脏病的交汇:通路与早期干预机会

The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention.
PubMed 文献 · Kidney Int Rep · 2025-12-30

本文综述MASLD与CKD的流行病学与机制证据,指出MASLD患者中CKD患病率更高,晚期肝病(如MASH和纤维化)者风险更大。共享机制包括胰岛素抵抗、系统性炎症、RAAS激活及肥胖、高血压、糖尿病等代谢危险因素,强调多学科管理及早期识别CKD并积极控制代谢风险。

要点

  • MASLD患者中CKD患病率更高,晚期肝病者风险更大。
  • 共享机制包括胰岛素抵抗、炎症、RAAS激活及代谢危险因素。
  • 建议对MASLD患者早期识别CKD并积极管理代谢风险。

核心结论

  • MASLD与CKD高度共病,早期识别CKD并积极管理代谢危险因素可能改善结局。

研究设计与样本

  • 综述,综合流行病学与机制证据,关注临床意义、筛查和管理策略。

主要发现

  • MASLD患者中CKD患病率 consistently 更高,晚期肝病如MASH和纤维化者风险更大。
  • 共享机制包括胰岛素抵抗、系统性炎症、RAAS激活及肥胖、高血压、糖尿病等代谢危险因素。

临床怎么用

  • 对MASLD患者应早期识别CKD,并采取多学科方法积极管理代谢危险因素。

局限性

  • 需进一步研究优化筛查策略、阐明病理生理通路及优化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are highly prevalent, overlapping conditions with significant health burdens. CKD affects > 650 million people worldwide and is a leading cause of morbidity and mortality, whereas MASLD affects nearly one-third of adults worldwide and increases risks of cardiovascular disease, kidney disease, and cancer. This review synthesizes epidemiologic and mechanistic evidence linking MASLD and CKD, with attention to clinical implications, screening, and management strategies. Studies consistently demonstrate a higher prevalence of CKD among patients with MASLD, with greater risk in those with advanced disease such as metabolic dysfunction-associated steatohepatitis and fibrosis. Shared mechanisms, including insulin resistance; systemic inflammation; renin-angiotensin-aldosterone system activation; and metabolic risk factors such as obesity, hypertension, and diabetes, contribute to kidney injury in this population. The coexistence of MASLD and CKD underscores the need for multidisciplinary approaches to care. Early identification of CKD in patients with MASLD, combined with aggressive management of metabolic risk factors, may improve outcomes. Further research is needed to refine screening strategies, clarify pathophysiologic pathways, and optimize treatment for this growing patient population.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sriperumbuduri S, Saravanan PB, Gupta G, et al. The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention. Kidney Int Rep. 2025. PMID: 41726005. doi:10.1016/j.ekir.2025.103757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。